MiR-27a inhibits the expression of several lipid metabolic genes, including SREBP1-2, FASN, and PPAR/, by reducing lipid synthesis and increasing lipid secretion from cells 92
Given the increasing availability of CV safety outcomes data for glucose-lowering medications, it has become apparent that certain agents within the GLP-1RA and SGLT-2 inhibitor classes reduce the risk of CV events in those with high-risk CV or CKD [16,17,18,19,20,21]
It is naturally found in every cell of the body and plays a key role in reducing oxidative stress, enhancing immunity, and assisting in the removal of toxins from the liver
Weight gain is not a common side effect of Soliqua (insulin glargine and lixisenatide)